Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 95 | BSPED2023 | Next issue

50th Annual Meeting of the British Society for Paediatric Endocrinology and Diabetes

Manchester, UK
08 Nov 2023 - 10 Nov 2023

Card image cap
The 50th Annual BSPED Meeting will take place at the Midland Hotel, Manchester from 8-10 November 2023.

Oral Communications

Oral Communications 10

ea0095oc10.1 | Oral Communications 10 | BSPED2023

The real-world experience of long acting growth hormone in children with growth hormone deficiency

Ramya Gokul Pon , Jarvis Charlotte , Laing Peter , Das Urmi , Ramakrishnan Renuka , Dharmaraj Poonam , Blair Jo , Didi Mohammed , Senniappan Senthil

Introduction: Long-acting growth hormone (LaGH) therapy has emerged as a newer treatment option for children, with the potential to improve adherence and compliance. Clinical trials have shown LaGH formulations to be effective and safe in children with GH deficiency (GHD). Somatrogon (Ngenla) is licensed for use in children with GHD over than 3 years of age.Objective: We report the real-world experience of using once wee...

ea0095oc10.2 | Oral Communications 10 | BSPED2023

A multidisciplinary approach to the growth hormone shortage

Burrows Ross , Foley Louise , Thirsk Claire

In January 2023 a Medicines Supply Notification (MSN) was issued by the Department of Health and Social Care (DHSC) regarding a shortage of Norditropin (somatropin) products. The MSN recommended that all patients on Norditropin FlexPro 10mg pens and NordiFlex pens (all strengths) be changed to Omnitrope SurePal. Each patient affected by the shortage needed to be informed of the issue, a new prescription issued, and training provided on the new device. Affected patients were id...

ea0095oc10.3 | Oral Communications 10 | BSPED2023

Evaluating the impact of a nurse education refresher session for families who have a child with adrenal insufficiency

Foley Louise , Burrows Ross

Parents of children with adrenal insufficiency are taught to administer a hydrocortisone intramuscular (IM) injection in an adrenal crisis. This involves assembling a needle and syringe and drawing up a dose from a vial. It is known that parents report high confidence levels in administration of the injection but at the time of acute illness actual administration is poor. This study set out to see if introducing a planned refresher session for families would impact confidence ...

ea0095oc10.4 | Oral Communications 10 | BSPED2023

The use of efmody (modified-release hydrocortisone, MRHC) in patients with congenital adrenal hyperplasia (CAH): initial experience and patient feedback

Baioumi Alaa , Chatterjee Sumana , Crowne Elizabeth

Background: Standard glucocorticoid therapy in CAH often fails to control androgen excess, causing glucocorticoid overexposure and poor health outcomes, particularly in adolescents. Efmody, a MRHC, has recently been licensed for CAH patients aged >12 years following a phase 3 study by Merke et al., 2021 demonstrating improved biochemical control in adults, steroid dose reduction over time, and patient-reported benefit.<stron...

ea0095oc10.5 | Oral Communications 10 | BSPED2023

Parental perspective on genitoplasty for girls with virilising congenital adrenal hyperplasia

Mariotto Arianna , Hennayake Supul , Cserni Tamas , Banerjee Indi , Busby Gail , Skae Mars , Patel Leena , Padidela Raja , Murray Philip , Nicholson Jaqueline , Jones Julie , Richmond Charlotte , Goyal Anju

Introduction: In response to the proposed move to decommission genitoplasty surgery for DSD, we investigated parental views on surgery for girls with virilising 46XX Congenital Adrenal Hyperplasia (CAH).Materials and Methods: In this prospective study, after ethical approval, parents of surgically treated CAH girls completed an electronic questionnaire.Results: 50 parents were cont...

ea0095oc10.6 | Oral Communications 10 | BSPED2023

An appraisal on the quality and readability of growth hormone therapy patient information developed by paediatric endocrine societies

McKechnie Jennifer , Qian Ho Zhe , Mason Avril , Wong Sze Choon

Background: In the UK, recombinant human growth hormone(rhGH) is approved for children with growth failure associated with six different conditions. According to NICE guidelines, clinicians should have a comprehensive discussion with patients and/or caregivers about treatment options. Research shows that patients retain only about 20% of the information provided during a consultation. This can be improved to around 50% when written information is also provided...